Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795776 | 0.82 | CCR5 (0.39) | DHODHCCR5HTR2AHTR2CHTR7 | |
| SCHEMBL22736534 | 0.78 | SLC6A2 (0.36) | FDFT1CHRNB2CHRNA4IDH1 | |
| SCHEMBL31463801 | 0.78 | CYP3A4 (0.38) | CHRNB2CHRNA4IDO1 | |
| SCHEMBL16763014 | 0.77 | CHRNA7 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL22736304 | 0.76 | ALOX5 (0.38) | FDFT1CHRNB2CHRNA4IDH1 | |
| SCHEMBL24021370 | 0.75 | NPC1 (0.47) | IDO1 | |
| SCHEMBL21795787 | 0.75 | NPC1 (0.47) | IDO1 | |
| Tert-Butyl Formate SCHEMBL28571195 | 0.75 | SLC6A2 (0.33) | CCR5CHRNB2CHRNA4 | |
| SCHEMBL22585502 | 0.75 | P2RX7 (0.39) | DHODHHRH3HTR2AHTR2CHTR7 | |
| SCHEMBL17064623 | 0.75 | SLC6A3 (0.43) | CCR5FDFT1CHRNB2CHRNA4IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | DHODH 470/4885CCR5 1890/4885FDFT1 273/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | DHODH 470/4885CCR5 1890/4885FDFT1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.